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ABSTRACT
Despite significant advances in our understanding ofthe biology and antigenic structure ofChlamydia
trachomatis, and the epidemiology and clinical spectrum of chlamydial disease, the magnitude of
morbidity from human chlamydial infections remains an important public health concern. Control
of chlamydial disease will likely depend on a multidisciplinary approach, including the development
of immunoprophylactic or immunotherapeutic strategies. Reasonable progress has been made in
understanding specific immune mechanisms that contribute to host immunity in experimentalmodels
of chlamydial infection. However, studies of human immunity have not been so successful. This
is particularly evident in that studies to address the development and role of mucosal immune
responses to urogenital chlamydial infections have not been forthcoming. The following review is
a briefsummary ofour current knowledge ofprotective immunity to chlamydial urogenital infections
offemales. It is not meant to be exhaustive, but instead to touch upon aspects ofprotective immunity
that have been described in both human and experimental animal models of chlamydial
infection. (C) 1996 Wiley-Liss, Inc.
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hblamydia
trachomatis is an obligate intracellular
acterial pathogen that primarily infects the
mucosal epithelium of the eye and urogenital tract.
Chlamydial urogenital tract infections cause a broad
range of clinical syndromes ranging from asymp-
tomatic infection to urethritis and epididymitis in
men, and cervicitis and salpingitis in women. In the
US alone, it is estimated that 4 million new cases
of chlamydial infection occur annually. Women ac-
count for 2-3 million of those infections of which
approximately 500,000 develop chronic salpingitis,
with 10% becoming infertile as a result of infection.
Although chlamydial infections constitute a major
public health problem worldwide, our understand-
ing of the immune responses that contribute to pro-
tective immunity are inadequately defined.
The development of protective immunity to
chlamydial infection most certainly involves the in-
teraction of both humoral and cell mediated im-
mune (CMI) responses. Antibody, cytokines, helper
T cells, and cytotoxic T cells have been implicated
as effectors in host immunity to experimental chla-
mydial infection.4’8’2’46’51’59’63 Their importance, or
lack of, is dependent on the animal model, route
of infection, infecting chlamydial strain, and a host
of other factors that vary from laboratory to labora-
tory. The development of chlamydial-specific anti-
body and cellular immune responses coincide with
recovery from chlamydial infection, and therefore
it is difficult to assign a predominant role to either.
A consensus has not been reached regarding the
preeminent protective antigen(s) or immune re-
sponse(s) that confer immune protection, however
significant progress has been made in regard to the
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fundamental role of anti-chlamydial antibody and
cellular immune responses. Definition of protective
immune responses and their cognate antigens is also
not well defined in human chlamydial infection, but
immune protection likely involves aspects of both
antibody and cell mediated responses. It is not
within the scope of this manuscript to review all
aspects of immunity to chlamydial infection. In-
stead I will focus on, and limit my discussion to,
protective immunity and aspects of the systemic
and local immune responses that develop following
mucosal chlamydial genital tract infection of
females.
Role of Antibodies in Protective Immunity to
Mucosal Chlamydial Infection
Studies ofchlamydial infection in experimental ani-
mals provide evidence that infection leads to the
development ofprotective immunity, but resistance
wanes over time and reinfection is possible.3’37’43’5
In the guinea pig models of ocular and genital tract
infection, antibodies appear to play a predominant
role in protective immunity. The concept that chla-
mydial-specific mucosal antibody may be an im-
portant mediator ofimmune protection is supported
by a number of studies, z9,3’3z’45,57 Those studies dem-
onstrate that ocular infection or enteric vaccination
of guinea pigs with viable chlamydiae, but not par-
enteral immunization, protects animals from rein-
fection. Protection is short-lived, associated with
the presence of secretory IgA, and is not transfer-
able with immune serum. Collectively those data
imply an essential role for secretory antibody in
protective immunity to experimental ocular chla-
mydial infection.
Rank et al.,46 using the guinea pig model of chla-
mydial genital tract infection, demonstrate a pre-
dominant role for antibodies in the resolution of
infection and protection from reinfection. The im-
portance of antibody in the resolution of infection
was demonstrated by treating guinea pigs with cy-
clophosphamide to suppress antibody responses,
while leaving CMI responses intact. Cyclophospha-
mide treated animals had intact CMI responses, but
did not produce antichlamydial antibodies and did
not resolve chlamydial infection. Furthermore, res-
olution of infection correlated with the presence of
mucosal anti-chlamydial IgG and IgA antibodies.4z
Resistance to re-infection in the guinea pig model
is also antibody dependent. Suppression of the anti-
body response with cyclophosphamide, followed by
infection and subsequent treatment with tetracy-
cline to cure infection, results in animals having
intact chlamydial CMI responses, but lack chlamyd-
ial specific antibody. Subsequent challenge of those
antibody-deficient animals results in infection.41 To
further elucidate the protective effect of anti-chla-
mydial antibody, naive guinea pigs were hyperim-
munized with immune serum (Ig fraction) and sub-
sequently challenged. Although passive immuni-
zation did not confer solid protection, shedding of
infectious chlamydiae was decreased. Collectively,
results from the guinea pig model of chlamydial
genital tract infection suggest that CMI alone is
not sufficient to confer protective immunity, and
provide indirect evidence that antibody plays a pro-
tective role.
The murine models of C. trachomatis, strain
mouse pneumonitis (MoPn), genital and respiratory
tract infection have also provided useful insights
into the mechanisms of protective immunity. In the
murine model of chlamydial pneumoniae, antibody
(immune sera) provides some degree of protection
when administered locally or systemically at the
time of infection.6’61 However, mice rendered anti-
body deficient by treatment with anti-I, antibody
are not more susceptible to primary respiratory tract
infection.58 Similarly, antibody depleted mice (anti-
l* treated) resolve chlamydial genital tract infection
with kinetics similar to immunocompetent mice.4
In that study, antibody depleted mice developed
chlamydial-specific delayed type hypersensitivity
and T cell proliferation responses, but failed to
produce either serum or secretory anti-chlamydial
antibody. Furthermore, antibody depleted mice
were resistant to secondary infectious challenge.
Therefore, unlike the guinea pig model ofchlamyd-
ial infection, where antibody plays a predominant
role in protective immunity, antibody appears not
to be an important aspect of protective immunity
in murine genital tract infection. The apparent dif-
ference in the protective role of antibody in the
mouse and guinea pig models of infection is not
understood, but has led to the hypothesis that CMI
responses alone are sufficient to resolve murine
chlamydial genital tract infection (discussed
below).
34
In humans, indirect evidence and correlative
data suggest that protective immunity does develop
following naturally acquired chlamydial infection.
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Early trachoma vaccine trials in humans and mon-
keys establish that vaccination confers some degree
of resistance to the homologous chlamydial strain,
but heterologous challenge leads to infections that
result in more severe disease. 14,15 Few studies have
examined whether naturally acquired genital tract
infection in humans provokes protective immunity,
but some studies suggest that prior infection may
confer some level of protection. For example, the
prevalence rates for acquiring chlamydial genital
tract infection are higher in adolescents than in
older adults, z7’47’48’49 Significantly lower isolation
rates for chlamydiae are also reported for men and
women who had prior chlamydial infection or non-
gonococcal urethritis, l’zz Collectively, those studies
imply that prior infection confers some degree of
protective immunity to chlamydial infection.
The immune mechanisms that confer partial
immunity to infection in humans have not been
identified, but experimental infections of humans
and subhuman primates with C. trachomatis demon-
strate that protection is short-lived and serovar
specific, za’56,6z Furthermore, the presence of serovar-
specific antibodies in local secretions correlates
with protection to reinfection, z’33 The precise role
of antibodies in protective immunity to human
chlamydial infections is undefined, but data from
experimental systems show that antibodies are
neutralizing. Monoclonal antibodies to both contig-
uous and conformational epitopes located on the
chlamydial major outer membrane protein
(MOMP) neutralize chlamydial infectivity for cul-
tured eukaryotic cells, passively protect mice
against chlamydial "toxicity" and prevent the in-
fection of monkey conjunctivae,
63 and thus support
the premise that antibodies might be protective
in vivo.
The literature is replete with serological studies
of patients with urogenital chlamydial infec-
tions,7’’’z’13’31’55 but few studies provide any direct
correlates with protective immunity. In one study
that addresses mucosal immune response in hu-
mans, Brunham, et al. analyzed the serum and se-
cretory anti-chlamydial antibody response in
women with uncomplicated C. trachomatis cervical
infection. They found that women from which the
fewest number of organisms were recovered had
the highest prevalence of secretory anti-chlamydial
IgA antibodies. Recovery of the organism from the
cervix was inversely correlated with the presence of
local anti-chlamydial IgA antibodies, and not serum
antibodies. Those data suggest that the secretory
antibody response may play a role in immunity to
chlamydial genital tract infection, but further stud-
ies are necessary to confirm and augment those
initial findings.
Although chlamydiae infect, replicate, and cause
immunopathological sequelae at the genital tract
mucosa, few studies have investigated the role of
mucosal immune responses in human infection.
Our understanding of the mucosal immune system
had advanced significantly in the past decade, and
therefore the opportunities exist for detailed analy-
ses ofthe mucosal immune response to human chla-
mydial genital tract infection. Such studies will ad-
vance our understanding of the role of mucosal
immune responses in protection and immunopatho-
genesis of chlamydial disease, and may provide im-
portant information that would be useful for the
design of specific control measures for chlamydial
infection.
Role of CMI Responses in Protective Immunity
to Mucosal Chlamydial Infection
Marked CMI responses, such as delayed type-hy-
persensitivity and antigen-specific T cell prolifera-
tion, are elicited following chlamydial infection of
humans and experimental animals,6,17’8’4’4s but little
is known about the effector role of those responses
in protective immunity. The most detailed informa-
tion regarding the characterization and identifica-
tion of Chlamydia-specific T cell responses comes
from studies using the murine model of chlamydial
genital tract infection.
Genital tract infection of mice with C. trachomatis
results in a self-limiting infection that resolves
within several weeks without antibiotic therapy,
thus providing a useful model for evaluating host
immunity. Rank, et al.44 used T cell deficient nude
mice to demonstrate the requirement for T cell
mediated responses in resolving chlamydial genital
tract infection. Genital infection of nude mice re-
suits in a chronic infection that persists for >9
months, and the adoptive transfer of spleen cells
enriched for T cells or B cells brings about the
resolution of infection. While the nude mouse
model clearly demonstrates the need for T cells in
protective chlamydial immunity, the contribution
of other lymphocyte populations or subpopulations
ofT cells has not been resolved. In contrast to the
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study by Rank, et al.,
44 Tuffrey, et al.,s3,s4 found that
T cell deficient mice resolve chlamydial genital
tract infection similar to infection of immunologi-
cally intact animals, and that the transfer ofimmune
lymphocytes did not confer additional protection.
It should be pointed out, however, that significant
differences exist in the experimental design and
the strain of C. trachomatis used for infections. For
the purpose of brevity, and because there exists
such dramatic differences in host immunity in these
two dissimilar models of infection, the remainder
of this discussion will pertain primarily to C. tracho-
matis MoPn infection.
Studies addressing the relative contribution of
T cell subpopulations in resolving chlamydial geni-
tal tract infection have been inconclusive, z6’38 For
example, despite in vivo depletion of either CD4+
or CD8+ T cell subpopulations with monoclonal
antibodies, mice resolve chlamydial infection with
kinetics similar to that of non-treated animals.
38
Those results suggest that either both T cell popu-
lations are capable of bringing about the resolution
of chlamydial infection, or that the depletion of cell
populations was incomplete. If both T cell popula-
tions are capable of resolving infection alone, then
perhaps a common immune mechanism such as
secretion of the chlamydiae-inhibitory cytokine in-
terferon-y plays a predominant role. Recently, how-
ever, the role of CD4+ cells and CD8+ T cells in
immune protection was re-evaluated,sz The adop-
tive transfer of CD4+ T cells, that were obtained
from mice following the resolution of primary chla-
mydial genital tract infection, conferred a significant
level of protective immunity to immuno-competent
naive animals. In contrast, the transfer of CD8+
T cells obtained from the same donor mice had no
effect. Furthermore, the protective CD4+ T cells
secreted lymphokines characteristic of both Thl
and Th2 type T cells. Therefore, those results con-
firm a primary protective role for CD4+ T cells, but
the relative contribution ofThl vs Th2 type helper
T cell responses was not clarified. In a recent study
by Cain and Rank, mononuclear cells isolated from
genital tract tissue of infected mice and stimulated
in vitro with chlamydiae, produced a Thl-like pat-
tern of cytokines. Those results imply that Thl-
type helperT cell responses coincide with the reso-
lution of genital tract infection. Clearly, though, the
precise role ofCD4+ and CD8+ T cells in protective
immunity to chlamydial genital tract infection has
not been established and other approaches must be
taken to address the contribution ofthese cell popu-
lation.
As an alternative approach to defining the capac-
ity of various T cell subpopulation to confer immu-
nity to chlamydial genital tract infection, T cell
lines and clones have been isolated and tested. The
initial testing of chlamydial specific T cell lines
demonstrated that lines enriched for either CD4+
or CD8+ T cells were capable of resolving infection,
although CD4+ cells were more efficient than CD8+
cell lines.39 Subsequently, both CD4+ and CD8+
T cell clones have been isolated and tested. Adop-
tive transfer experiments using T cell clones and
the T cell deficient nude mouse model of chlamyd-
ial genital tract infection demonstrate that both
CD4+ and CD8+ T cell clones are capable of resolv-
ing infection. 19,z The protective T-helper-cell clone
in those studies was of the Thl phenotype, secre-
ting interferon-y, IL-2 and TNF-ot.z Recipient
mice receiving this clone and infected with Chla-
mydia produced low levels of anti-chlamydial anti-
body, suggesting that protection might result from
immune effector functions other than antibody. A
CD8+ T cell clone has also been shown to be capa-
ble ofresolving infection in nude mice.
’9 The ability
of the CD8+ T cell clone to resolve infection was
not as pronounced as the CD4+ clone (55% vs. 81%
resolution, respectively), but nevertheless a positive
effect was observed. A common feature of the pro-
tective CD4+ and CD8+ clones was production of
interferon-y and TNF-ot, which has led to the sug-
gestion that these cytokines play an importantt role
in protective immunity.
Because of the obligate intracellular lifestyle of
chlamydiae, cytotoxic T cells (CTL) are thought to
contribute to protective immunity. Until recently,
investigators were unable to demonstrate convinc-
ingly that CTLs functioned in the anti-chlamydial
immune response, zs,3s,36 However, recent studies
have demonstrated that MHC class I restricted
CTLs are capable of lysing Chlamydia-infected
cells.4,s The function of chlamydial CTLs in vivo
is not understood, but the adoptive transfer of a
CTL line decreased the chlamydial burden in sys-
temically infected ’mice and the effect was depen-
dent upon interferon-y,s Obviously, though, those
studies need to be confirmed in a more relevant
model of mucosal chlamydial infection. Thus, our
understanding of the role of CD8+ T cells in host
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immunity to chlamydial infection is incomplete,
and additional studies are needed to determine
more precisely the importance of these cells and
the mechanism(s) by which they exert their effect
in vivo.
Recent Investigations Using Gene Knockout
Mice to Study Immunity To C. trachomatis
Genital Tract Infection
The following data come from our recent studies
using gene knockout mice to delineate the roles of
T cell subpopulations and antibody in immunity to
chlamydial genital tract infection. We recognize that
the murine model of chlamydial genital tract infec-
tion has limitations in regard to its applicability to
human infection. However, the murine model does
allow us to analyze many aspects of host immunity,
and provides a basis from which to formulate studies
to address immunity to human chlamydial infection.
Gene targeting, a method by which specific
genes are altered in embryonic stem cells and subse-
quently passed through the germ line, has been
used to generate mice that are devoid of cell surface
expression of either MHC class I, MHC class II, or
Ig molecules. MHC class 1-deficient animals have
been generated by inactivation of the gene for [3z-
microglobulin,z4 which is required for the proper
assembly and cell surface expression of the MHC
class molecule; as a result these mice are deficient
in CD8+ T cells. Mice that are devoid of cell surface
expression of MHC class II molecules, derived by
inactivation of the I-A gene, are deficient in CD4+
T cells. 16 B cell development is arrested at the pre-
B cell stage in mice having a targeted disruption of
the pM gene, and these mice lack cell surface IgD
and IgM and fail to produce immunoglobulin (Ig). z3
In our recent studies we examined the capacity of
MHC class I-, MHC class II-, or Ig-deficient mice
to resolve C. trachomatis genital tract infection and
to resist secondary infectious challenge. A very brief
summary of our findings are presented in Table 1.
To delineate the possible roles of serum and
secretory antibody, and MHC class I- and class II-
restricted T cell responses in the development of
protective immunity to chlamydial infection, we
evaluated chlamydial genital tract infection in spe-
cific gene knockout mice. z8 Female mice were in-
fected vaginally with C. trachomatis strain MoPn and
infection was monitored by swabbing the vaginal
vault and enumerating inclusion forming units on
a HeLa cell monolayer. Control mice and mice defi-
cient in eitherMHC class molecules or Ig resolved
primary chlamydial infection by about 4 weeks post-
infection. Shedding of infectious chlamydiae was
not significantly different at any time following in-
fection. Conversely, mice deficient inMHC class II
molecules failed to resolve infection, and remained
culture positive and continued to shed large num-
bers of chlamydiae (> 100,000 IFUs), throughout
the observation period (>70 days).
The humoral and cell-mediated anti-chlamydial
immune responses were evaluated during the
course of primary chlamydial infection. Control and
MHC class I-deficient mice produced high titers of
serum anti-chlamydial antibodies, consisting pri-
marily of IgG2a, IgG2b, and IgA subclasses. Ig defi-
cient mice did not produce detectable anti-chla-
mydial antibodies and MHC class II-deficient mice
produced only low levels of IgG2b and IgG3 anti-
bodies. Vaginal washes were analyzed for chlamyd-
ial-reactive antibody, and only control and MHC
class I-deficient mice were found to be positive
(anti-Chlamydia IgA). Control, MHC class I-de-
ficient and Ig-deficient mice had comparable
chlamydial-specific CMI responses (delayed type
hypersensitivity responses, T cell proliferation) fol-
lowing primary infection, whereas MHC class II-
deficient mice were negative. Collectively, those
results suggested that MHC class II-restricted
T cell responses were necessary to bring about the
resolution of primary chlamydial genital tract infec-
tion, whereas infection resolved typically in the ab-
sence of antibody or MHC class I-restricted
T cell responses.
Following the resolution of primary chlamydial
genital tract infection control, MHC class I-defi-
cient and Ig-deficient mice were rechallenged to
assess the development ofacquired immune protec-
tion. Control and MHC class I-deficient mice were
resistant to reinfection. Although some mice were
reinfectable (-30%) they shed fewer infectious
chlamydiae (4 to 5 log10 lower than primary infec-
tion) and for a shorter period of time (7-10 days vs.
28-30 days for a primary infection). Conversely, all
Ig-negative mice were susceptible to reinfection,
but this secondary infection was characterized by
the shedding of fewer chlamydiae and an infection
of shortened duration.
Our results from studying chlamydial genital
tract infection in gene knockout mice reveal that:
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TABLE I. Summary of immune responses and infection outcome following genital tract infection of control
and gene knockout mice
Mouse Strain
MHC class MHC class II B cell
Control deficient deficient deficient
Resolve infection yes yes no yes
Anti-Chlamydia antibodies
serum yes yes no no
vaginal wash yes yes no no
Anti-chlamydial CMI yes yes no yes
Resistant to 2 yes yes NT no
Infectious challenge
aRefer to the text for detailed explanation of these findings.
blow levels of anti-Chlamydia IgG2b and IgG3 were detected.
CNot tested.
1) MHC class II-restricted T cell responses are ab-
solutely necessary to resolve primary infection; 2)
MHC class I-restricted responses are neither neces-
sary to bring about the resolution of primary infec-
tion nor to resist secondary challenge. However, we
can not exclude the possibility that those responses
play an important role in immunity to chlamydial
infection in the immunocompetent animal; 3) Cell-
mediated immunity plays a dominant role in resolv-
ing established chlamydial infection; 4) The pres-
ence of local (vaginal) anti-Chlamydia antibody at
the time of inoculation prevents colonization and
subsequent infection.
SUMMARY
Ch/amydia-specific antibody and CMI responses
play key roles in immunity to chlamydial genital
tract infection. Local IgA antibodies appear to pro-
mote resistance to reinfection, whereas CMI re-
sponses do not protect against reinfection per se,
but instead promote the resolution of established
infection. Although the presence of antibody at the
site of infection (genital tract) can prevent coloniza-
tion/infection, sterilizing immunity through neu-
tralizing antibody might be difficult to achieve. If
these findings hold for human chlamydial infection,
then the therapeutic value of a vaccine solely tar-
geted to elicit neutralizing antibody might be debat-
able. Although such a vaccine would be ideal, it is
unlikely that long-lived protective immunity could
be achieved using a vaccine designed to elicit only
neutralizing antibodies. Perhaps a better vaccine
strategy might be to concentrate efforts on immuni-
zations that stimulate protective cell-mediated im-
munity, or cell-mediated immunity and neutraliz-
ing antibody. Although significant advances have
been achieved in describing protective immune re-
sponses to chlamydial genital tract infection, gaps
still remain in our understanding of host immunity.
The effector cells of CMI that resolve infection
have neither been characterized nor their antigenic
specificity determined. Furthermore, once protec-
tive antigens have been identified it must be deter-
mined if they can be administered in a manner that
stimulates protective immunity in a naive host.
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